Li Huang

Li Huang

Auto-generated profile, based on publicly available information

Li Huang

University of Pennsylvania 1 Department of Biomedical Sciences Philadelphia, Pennsylvania

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2026 in Cancer Immunology Research
Verified
Journal Article
Closed access
KBKhuloud Bajbouj
Khuloud Bajbouj
ZXZebin Xiao
Zebin Xiao
LTLeslie Todd
Leslie Todd
LHLi Huang
Li Huang
TPTyler Ellis Papp
Tyler Ellis Papp
EPEllen Puré
Ellen Puré
Fibroblast activation protein (FAP), which is highly expressed on cancer-associated fibroblasts (CAF), is a promising therapeutic target to achieve normalization of the tumor microenvironment. We previously established an ex vivo retroviral-transduced FAP-specific chimeric antigen receptor (FAP-CAR) T-cell approach to deplete FAP+ CAFs that resulted in delayed tumor growth associated with disruption of desmoplastic matrix and enhanced immune cell infiltration and reversed immune exclusion and immunosuppression. In this study, we describe an in vivo strategy for generating FAP-CAR T cells using anti-CD5–conjugated targeted lipid nanoparticles (tLNP) encapsulating FAP-CAR mRNA and assessed the efficacy of this approach compared with adoptive transfer of retrovirus-transduced CAR T cells in a preclinical model of pancreatic ductal adenocarcinoma. With transient CAR expression in >45% of splenic, >69% of circulating, and >35% of tumor-infiltrating T cells, the abundance of peripheral and intratumoral FAP-CAR+ T cells detected following a single intravenous dose of FAP-CAR mRNA tLNPs was greater than that detected following administration of 1 × 107ex vivo retrovirally transduced FAP-CAR T cells. Furthermore, in vivo mRNA CAR T-cell engineering resulted in as good or greater inhibition of tumor growth as compared with adoptive transfer of ex vivo retroviral-engineered T cells. Given that in vivo generation of CAR T cells resulted in transient CAR expression and circumvented the need for autologous T-cell isolation, viral vectors, and lymphodepletion, this platform represents a potentially safer, more accessible, and cost-effective method for targeting stromal cells to normalize the tumor microenvironment in desmoplastic tumors and has potential implications for tumor antigen–targeted CAR T cells.


2 April 2026
Verified
Other
Open access
KBKhuloud Bajbouj
Khuloud Bajbouj
ZXZebin Xiao
Zebin Xiao
LTLeslie Todd
Leslie Todd
LHLi Huang
Li Huang
TPTyler Ellis Papp
Tyler Ellis Papp
EPEllen Puré
Ellen Puré
Supplementary Figure 7. Robust and consistent anti-tumor activity of in vivo generated FAP-CAR T cells across multiple experiments.

2 April 2026
Verified
Other
Open access
KBKhuloud Bajbouj
Khuloud Bajbouj
ZXZebin Xiao
Zebin Xiao
LTLeslie Todd
Leslie Todd
LHLi Huang
Li Huang
TPTyler Ellis Papp
Tyler Ellis Papp
EPEllen Puré
Ellen Puré
Supplementary Figure 1. Flow cytometry gating strategy.

2 April 2026
Verified
Other
Open access
KBKhuloud Bajbouj
Khuloud Bajbouj
ZXZebin Xiao
Zebin Xiao
LTLeslie Todd
Leslie Todd
LHLi Huang
Li Huang
TPTyler Ellis Papp
Tyler Ellis Papp
EPEllen Puré
Ellen Puré
Supplementary Figure 3. Kinetics of CD5-tLNO-FAP-CAR expression in primary murine T cells in vitro 24-, 48-, and 72-hour post incubation.

2 April 2026
Verified
Other
Open access
KBKhuloud Bajbouj
Khuloud Bajbouj
ZXZebin Xiao
Zebin Xiao
LTLeslie Todd
Leslie Todd
LHLi Huang
Li Huang
TPTyler Ellis Papp
Tyler Ellis Papp
EPEllen Puré
Ellen Puré
Supplementary Figure 8. Comparative efficacy of in vivo and ex vivo CAR T cells.